Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40–70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipi...

Full description

Saved in:
Bibliographic Details
Published in:Clínica e investigación en arteriosclerosis (Internet, English ed.) English ed.), 2020-01, Vol.32 (1), p.29-31
Main Authors: Piqueras Ruiz, Sandra, Parra Virto, Alejandro, Torres do Rego, Ana, Demelo Rodríguez, Pablo, Álvarez-Sala Walther, Luis
Format: Article
Language:English
Subjects:
Alirocumab
c-LDL
Cardiovascular events
Evento cardiovascular
Inhibidores de PSCK9
iPCSK9 inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40–70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipid-lowering treatment. A discussion will be presented on the importance of maintaining low cholesterol levels in order to achieve a greater benefit, according to the latest published clinical studies. Los inhibidores de la PCSK9, disponibles desde el año 2015, son capaces de reducir la concentración de colesterol transportado en las lipoproteínas de baja densidad entre un 40-70% y, por consiguiente, disminuir el riesgo cardiovascular. Presentamos un caso en el que un episodio cardiovascular grave apareció al espaciar la administración del tratamiento hipolipidemiante; discutiremos la importancia de mantener una concentración baja de colesterol, para conseguir un mayor beneficio clínico según los últimos estudios publicados.
ISSN:2529-9123
2529-9123
DOI:10.1016/j.artere.2019.04.002